Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339688 | 1.00 | GFER (0.64) | GFERKMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL9853483 | 0.83 | MAPT (0.53) | GFERKMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL17697018 | 0.82 | MAPT (0.52) | GFERKMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL12253477 | 0.78 | SMN1; SMN2 (1.00) | GFERKMT2ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL1341096 | 0.78 | SMN1; SMN2 (0.77) | GFERKMT2ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL11459872 | 0.78 | SMN1; SMN2 (1.00) | GFERKMT2ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL9043048 | 0.78 | KMT2A (0.54) | GFERKMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL9043486 | 0.78 | KMT2A (0.54) | GFERKMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL1341093 | 0.78 | SMN1; SMN2 (0.77) | GFERKMT2ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL11070779 | 0.77 | GAA (0.47) | GFERKMT2ASMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070114155-A1 | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL RAFFINAGE FRANCE (FR) | 2007-05-24 | — | — | US | claimed |
| CN-1845789-A | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL FRANCE (FR) | 2006-10-11 | — | — | CN | claimed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-8535515-B2 | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL FRANCE (FR) | 2013-09-17 | — | — | US | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| CN-1845789-B | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL FRANCE | 2011-05-11 | — | — | CN | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-0564397-A1 | Antiatherosclerotic substituted phenylquinazoline derivatives | SANDOZ LTD. (CH) | 1993-10-06 | — | — | EP | disclosed |
| EP-0523846-A2 | 1,4-Benzodiazepines with 5-membered heterocyclic rings | MERCK & CO. INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0272866-A1 | 1,4-Benzodiazepines with 5-membered heterocyclic rings | MERCK & CO. INC. (US) | 1988-06-29 | — | — | EP | disclosed |
| US-4472435-A | HYPOTENSIVE AGENT, ALDOSTERONE ANTAGONIST, AND TREATMENT OF HEPATITIS | HOFFMAN-LA ROCHE INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0045450-B1 | BENZOPHENONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
| EP-0045450-A1 | Benzophenone derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | GFER 697/4885KMT2A 1526/4885SMN1; SMN2 2958/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | GFER 697/4885KMT2A 1526/4885SMN1; SMN2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.